Background: Randomized, double-blinded, placebo-controlled trials have significant impact on clinical practice. The ultimate goal of a clinical trial of therapy for acute ischemic stroke (AIS) is to compare 2 interventions. Challenges may include interventional therapy standardization, enrollment rate, patient selection, biases, data and safety monitoring, reporting, and financial and logistical support.
Clinical trial use in medicine dates back to 1931, when the effect of sanocrysin in pulmonary tuberculosis was studied, with allocation determined by the flip of a coin. 1 Clinical trials now have dedicated specialists in all aspects of trial design.
The effect of clinical trials on clinical practice has been shown previously. In ischemic stroke secondary prevention, publication of the results of the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial (comparing aspirin to warfarin for intracranial stenosis, and showing high recurrent stroke with the use of aspirin or warfarin) was followed by publication of a registry for use of a new intracranial stent, leading to a significant increase (by 763%) in the frequency of intracranial stenting. [2] [3] [4] This may show the reverse impact on the use of intracranial stenting in treating intracranial stenosis, following the more recent publication of a prospective randomized, controlled clinical trial comparing intracranial stent to optimal medical therapy in Ն70% of symptomatic stenosis cases, with superiority of medical therapy. 5 The International Subarachnoid Hemorrhage Trial (ISAT) results, which showed superiority of endovascular transarterial coil embolization over surgical clipping in ruptured cerebral aneurysms, has changed the way we treat aneurysm nowadays. 6 The number of aneurysms treated with coiling has increased by 315% between 2001 and 2008. 7 In the past half century, the number of controlled clinical studies has increased as it became the preferred method for establishing clinical evidence. From 1995 to 1999 there were 178 controlled trials of therapy for acute ischemic stroke (AIS). 8 The trend in AIS trials has been toward an increase in sample size and a decrease in time window. 9 Despite improvements, AIS trials lag behind other specialties such as oncology in the level of design sophistication to overcome persistent limitations. 10 Moreover, differences exist between drugs and devices in terms of regulation and approval by regulatory agencies. 11 Drugs typically enter the market after a randomized controlled trial (RCT) shows safety and clinical efficacy. An RCT of endovascular AIS therapy is challenging to conduct; only one phase III AIS endovascular clinical trial (Prolyse in Acute Cerebral Thromboembolism [PROACT] II 12 ) has been completed. Interventional Management of Stroke III (IMS III) 13 is a phase III trial comparing an interventional approach to standard of care (IV recombinant tissue plasminogen activator) that was halted recently and will be published in the near future. Designing AIS endovascular interventional clinical trials is a daunting task, facing several challenges such as the best design, sample size, rate of recruitment, choice of outcome measure, evolving iterative device technology, informed consent, procedure standardization, and other logistic issues. 14 For additional references, we refer interested readers to Stroke Therapy Academic Industry Roundtable (STAIR) statements and the Clinical Trials in Neurology textbook. [15] [16] [17] [18] [19] [20] [21] [22] ETHICAL CONSIDERATIONS Some of the ethical issues that may be encountered are the presence or lack of equipoise, 23 the randomization process, the cost of care within the trial, and informed consent.
As experience with endovascular therapy (ET) improves, efficacy becomes supported by anecdotal evidence that, by some investigators, precludes enrollment. The fact that there is no firm evidence to support which patients may or may not benefit from ET provides equipoise to legitimately conduct an RCT. These issues may be addressed by including newer devices and scientifically convincing interested parties of the presence of equipoise.
Moreover, the randomization process may be implemented to allow more patients to be randomized to intervention. This would be by using different rates of randomization, imaging-based randomization, concurrent controls, and historical controls (see the following sections).
Informed consent. Detailed discussion of the informed consent (IC) in AIS trials is beyond the scope of this review. The sophistication of the ET, standard of care, and variability of the natural history of untreated patients are all elements that make the process of emergency IC complex. 24, 25 Considering emergency waiver of consent in some cases (such as basilar artery thrombosis and coma) but not in all cases would require public discussion for allowing community, next of kin, or legal representative consent; in other, milder stroke cases, direct IC can be obtained. 24, 25 Telestroke may also allow consenting patients' families remotely and enrollment of drip-andship patients.
Ethics committee and institutional review board. The federal government is evaluating the current rules for conducting research in human subjects, which may help to improve institutional review board (IRB) process in general and streamline AIS trial research without undue bureaucracy. 26 The US Department of Health and Human Services is considering modification of IC-to be easier to understand, to provide uniform data protection, and to avoid duplicate paperwork-as well as electronic case report forms (CRFs), a more systematic approach to collecting adverse event data, to match the review requirements with the risk posed and enable multicenter trials to be supervised by a single IRB. 26 
CLINICAL TRIAL DESIGN CONSIDERATIONS
The clinical trial definition of statistical power and classification of various phases is summarized in table 1, with a typical timetable of a medical device study summarized in the figure. 27 Introduction of medical devices to the market may start with preclinical animal, angiographic, clinical, and histologic studies, sample size calculation, and then establishment of the trial protocol, CRF design, budget, clinical trial agreement, site selection, investigators' meeting, IRB approval, site initiation visit, audit, midterm analysis, study completion, queries and data cleaning, and study closure.
Classic trial design phases are as follows: Preclinical-animal safety/feasibility study: devices are tested for trackability, deliverability, and performance of the intended use, with histopathologic confirmation of safety and clot removal.
Phase I-human safety/feasibility and efficacy exploratory device trial: a classic device study is within 8-hour time/imaging/combined windows of AIS patients with NIH Stroke Scale (NIHSS) score Ն8. Proposed number of patients to be enrolled is 40 to 50.
Phase IIA-human safety, feasibility, and efficacy exploratory device trial: a study within 8-hour time/ imaging/combined windows of AIS patients with NIHSS score Ն8, with noninferiority/equivalency comparison to an existing device approved by the US Food and Drug Administration (FDA). Proposed number of patients to be enrolled is 75 to 125 per arm (total of 150 -250).
Phase IIB-device use and application study for 3 to 5 years following FDA approval, to test real-life safety and feasibility, to allow introduction of new design iterations, and to enhance clinical application before planning the RCT. Proposed number is 1,000 to 3,000.
Phase III-RCT efficacy trial with lead-in phase of AIS ET vs the best clinical care.
Phase IV-postmarketing study to allow monitoring of the device in real-world practice. Table 2 shows select AIS trials and their designs.
Comparative vs single-arm studies. Prospective singlearm studies. The FDA pathway to approval of such devices has been via the 510(k) process, based on safety and angiographic revascularization endpoints. The evidence provided by single-arm prospective AIS device trials and FDA clearance (510(k)) has permitted incorporation of ET in routine AIS treatment. Anecdotal evidence thus became convention. However, increasing demand from the stroke neurology community for a higher level of scientific evidence resurrected interest in RCTs. 28 Challenges to stroke device RCT design need to be considered, given the complexity of ET (variability and lack of standardization) vs medical care (simple and standardized). An additional consideration is to conduct a large postmarketing study following the phase II (510(k) approval) trial, allowing time to standardize application of the new device and its design reiteration prior to RCT with an embedded lead-in phase. Comparative effectiveness research. According to the Institute of Medicine, comparative effectiveness research (CER) is defined as "the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health care at both the individual and population levels." 29 More recently, the US Congress has taken CER seriously and boosted its funding. 30 However, CER is not easily applied to complex ET, and RCT design needs to be addressed as a prerequisite.
ENDOVASCULAR AIS THERAPY TRIAL CHAL-

LENGES AND CONSIDERATIONS Sample size.
Estimation of sample size based on statistical power (table 1) is a key to finding treatment effect. The sample size estimation requires 4 elements: interventional therapy presumed effect; standard of care event rate; power needed (0.7, 0.8, 0.9); and significance level (␣: 0.05, 0.10). Small sample size may partly explain failure in many stroke trials. 31 One report showed that 72% of AIS phase III trials were underpowered to Ͻ0.90 level and overestimated their intervention effect or underestimated the control arm event rate. 31 The possibility of not finding a treatment effect based on an optimistic assumption should be weighed against the future ramifications of a negative trial.
Enrollment challenges. Investigators often use the "1 patient per month per center" enrollment rate rule. One other assumption is the rule of thirds: centers will enroll approximately 1/3 of the number of patients predicted; 1/3 of the centers will enroll their target numbers; and 1/3 will perform far below expectations. 32 Some of the proposed solutions are summarized in table 3. These include increasing the proportion of patients randomized to ET; perform- ing an unbiased trial; emphasizing the presence of equipoise; having a flexible protocol in terms of inclusion criteria and ability to include device iterations; replacing low-enrolling sites; and allowing for high-enrolling sites with low protocol deviations to be part of the publication committee. Telestroke has the potential for allowing drip-and-ship patient enrollment.
Time vs imaging-based enrollment (responders vs nonresponders paradigm).
There is a controversy about using time from symptom onset vs multimodal imaging vs using both as the main inclusion criteria for endovascular AIS trials. 33 MRI diffusion and perfusion sequences are used in triaging patients with AIS for ET. 33 The imaging criteria of interest to use for randomization (the amount of mismatch) is highly dependent on technical and software factors. Moreover, in the bridging IMS trial, outcome has been found to be time-dependent. 34 However, the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) study, testing whether MRI selection of patients for AIS interventional therapy (using the Merci or Penumbra device), is near completion and will help to clarify the imaging role in future trial design. 35 More recently, the clot length as measured on an ultrathin head CT scan has been correlated with lack of response to systemic IV recombinant tissue plas- Table 3 Challenges for planning interventional management of acute ischemic stroke trials Challenges Suggestions to overcome the challenges
Financial and funding for clinical trials Joint sponsorship between government and industry
Reluctance in enrolling patients into standard of care vs interventional therapy or vice versa. Clinical practice pattern of the convention that intra-arterial thrombolysis is effective and the paradox of enrolling patients into placebo in clinical trial. 63 1. Different rate of randomization to endovascular vs medical therapy, similar to PROACT and IMS, 2:1. The new concept of randomization between existing approved devices vs newer device is an improvement over the single-arm studies but would not compare the endovascular therapy to standard of care 2. Selection of sites that favor endovascular therapy vs sites that favor standard medical therapy (needs statistical adjustment)
3. Selecting and identifying the subgroup that would benefit the most from endovascular therapy to reduce the sample size by having the largest potential difference in outcome: e.g., 0-4.5 h IV patients with NIHSS Ն8 with large penumbra or large-vessel occlusion on CTA or clot length on ultrathin plain CT scan to randomize to IV vs IV and IA (THERAPY Trial NCT01429350) minogen activator therapy when the clot length exceeded 8 mm. 36 Using clot length as the main inclusion criterion, a randomized clinical trial (the THERAPY Trial) has been launched. 37 Theoretically, responder-based selection may reduce the sample size, increase power, and more likely find a treatment effect. Disadvantages may include slow enrollment, limited generalizability, and prolonged duration.
Selection bias. Strict selection criteria would limit the generalization of the trial results, and liberal selection criteria may dilute the effect of the intervention of interest. Trials with unclear subject allocation blinding and randomization method showed larger estimates of effect when compared with concealment trials. 38 Investigator meetings may play a pivotal role in ensuring minimal selection bias to improve results credibility.
Choice of study endpoint: angiographic and clinical outcomes. Angiographic revascularization. The most commonly used successful revascularization endpoints are the Thrombolysis in Myocardial Ischemia (TIMI) and Thrombolysis in Cerebral Ischemia (TICI) grading scales. Scale outcomes of TIMI 2, TICI 2, TICI 2b, or higher have all been considered successes. More recently, in the SWIFT trial (Solitaire FR With Intention for Thrombectomy, a trial comparing the efficacy and safety of the Solitaire Stent Retriever with the Merci device), the design was based on recanalization success. This was defined as successful recanalization of TIMI 2 or higher without symptomatic intracranial hemorrhage. 39, 40 Adhering to a well-defined angiographic grading scale is important to enable comparison of trials. Clinical outcome measure. Modified Rankin Scale (mRS; a 7-point scale) score at day 90 has been commonly used for the primary clinical endpoint in AIS trials (table 4) . Other endpoints used in stroke trials are Barthel Index (BI), NIHSS, and global scale (combining more than 1 scale) (table 5) . 41, 42 One study that compared the statistical power for a range of mRS, BI, and global scale on the basis of data from the Glycine Antagonist in Neuroprotection International Trial on detecting a treatment difference found that the mRS is the most powerful scale. 41 On the basis of the authors' analysis, the statistical power improved by using mRS vs BI Ն60 and reducing sample size by 84% (73% for patient-specific BI and 81% for global score). A similar finding was established by National Institute of Neurological Disorders and Stroke investigators, as the mRS dichotomized at Յ1 was found to be the most effective measure in identifying effectiveness of IV tissue plasminogen activator (tPA). 43 Another choice is endpoint trichotomization (for example, mRS Յ1, Յ2, and more than 2, or BI Ն60, Ն95, and less than 60), shift analysis of mRS shows how many people improve to a better scale, or patient-specific based on initial stroke severity may be more sensitive given the significant heterogeneity of the AIS population. 44 An example of the importance of the choice of primary clinical outcome endpoint is evident in the European Cooperative Acute Stroke Study II trial. 45 If the primary endpoint selected for the trial was mRS shift analysis or dichotomized at Յ2, then the trial would have been positive in favor of IV-tPA. 45 
Novel clinical trial designs. Choices of control group.
The gold standard is the contemporary randomized control, where participants are allocated randomly to treatment or control groups across all participating sites at all time points.
The use of this gold standard control type may lead to selection bias or low enrollment based on investigator belief; hence, concurrent control may be considered. The concurrent control arm would be from participants enrolled approximately at the same time from centers that do not adopt ET in their pathway and protocol or at which it is not feasible to send patients to ET because of time constraints. The concurrent control has the potential advantages of higher enrollment rate, shorter trial period, and method of allocation based on physician-/centerspecific conventions. However, it is associated with an inherent selection bias.
Another type of control is historical control. Historical controls are comparable subjects from a previous study with similar inclusion and exclusion criteria that did not include the interventional therapy of interest, compared with a new intervention used in a single-arm prospective trial. An example of historical control is when the Penumbra Pivotal Trial enrolled a similar number of patients and used inclusion/exclusion criteria similar to those in the MERCI Table 5 Clinical and angiographic outcome choices in selected acute ischemic stroke clinical trials trial. 46, 47 The advantage of historical control is that all participants will receive the new intervention; this may resolve the ethical dilemma of some treating physicians and potentially may cut the trial cost and period in half. Selection bias and credibility are the main drawbacks of historical controls. The time difference between the historical control in a prior trial and the new trial time of enrollment may produce undetectable time-shift bias. Moreover, historical data are usually incomplete and lack uniformity. If some of the historical control data can be used, then hybrid control could be considered. This would allow a combined contemporary randomized control plus historical control. 48 The historical controls have to be recent, must share similar inclusion/ exclusion criteria, and must be enrolled by the same institution/investigators.
A multidimensional pooled control function model was created to pool data from all AIS control arms published between 1994 and 2008. 49 This is an intriguing method allowing pooling of multiple con-trol groups according to baseline NIHSS score and age, but they still inherently share similar limitations of using historical controls. 49 Finally, ongoing prospective outcome research registries may be used as control groups, but these may have similar limitations of missing data, selection bias, lack of oversight and protocol uniformity, and analysis complexity.
Bayesian design. The Bayesian approach for statistical inference in AIS trials has been debated. 50 -52 The true innovation of the Bayesian approach is seen in cancer trials, given the small population of specific cancer type and more patients interested in the intervention. 53 The Acute Stroke Therapy by Inhibition of Neutrophils trial used the adaptive dose-response Bayesian approach in real-time decision-making, to the level of whether there is need for the next observation at all. 54 A conventional approach to statistical inference in clinical trials is the "frequentists' approach," where there is a very restricted sense of probability. The Bayesian approach uses current available data to create historical information (or posterior distribution) to create probabilities of future results (or anterior distribution). Moreover, the Bayesian approach could be used to determine when enough data are collected to create a statistically significant conclusion to the trial. Those 2 Bayesian features ensure that the power of the study is significant even with a limited sample size. The Bayesian approach is helpful in showing probability of relative effectiveness between 2 therapies with real-time adaptive statistics. 55, 56 Some of the advantages and limitations of the Bayesian approach are listed in table 6. Bayesian approaches can provide a potential platform for device companies to create hierarchical models to increase power of studies using fewer subjects; however, more studies using this design are needed. Test concepts with devices. In this paradigm, the clinical trial design is testing a concept with one or multiple devices. For example, the IMS trial premise of testing the endovascular concept rather than the efficacy of a single endovascular device would allow the flexibility for interventionalists to use what they believe would work best. 13 If the study is positive for the interventional approach, it remains to be seen how the FDA would react. One advantage to such an approach is that a benchmark for clinical outcome in the standard of care and combined interventional approaches could be established.
IV regulatory considerations. The FDA clearance (510(k)) process after a safety/angiographic efficacy single-arm trial with comparison to a predicate device (historical control) and, more recently, after device-vs-device trials, is a way to introduce the device into the market. There has been concern that devices are not held to the same approval standards as drugs. 57 It is unknown which mechanical thrombectomy device can be tested in an RCT and when, since the feasibility of the new technology and identification of the right subgroup of patients are concerns.
FINANCIAL ASPECTS OF CLINICAL TRIALS
Financial and logistic support. The 2 main criticisms of RCTs are the long duration and the cost. Endovascular AIS intervention trials are expensive and may be the right setup for joint sponsorship between national government funding agencies and industry. 16 -20 There are concerns about the credibility of the results and publication bias when industry is involved, however. 58, 59 If the studies are solely sponsored by industry, then they are likely not to be published if negative, and they are not likely to be completed if futility analysis is performed. 58 It is important to assure the investigators that the industry sponsor guarantees no censoring of manuscripts, irrespective of the result. This underscores the importance of joint sponsoring of studies by a national agency and the medical device industry, to increase their credibility.
Costs of overtreatment are less than costs of undertreatment. Traditional paradigms for designing clinical trials have been based on the principle that a new treatment cost is less than the cost of standard treatment because of potential downstream savings on chronic care costs. This concept has significant implications for AIS stroke therapy with newer, expensive endovascular devices. Cost-effectiveness analysis of AIS endovascular trial design is a critical consideration for interested government and private insurance agencies.
Pay per procedure within and outside the trial. One intricate financial aspect of clinical trials is the financial complexity of payers, institutions, trialists, and proceduralists. The payers are asking to identify standard-of-care vs study-related activities. The proceduralists may have concerns about the consequences of a given trial result on the prospect of providing coverage to other patients outside the trial inclusion criteria, i.e., lack of generalizability. Such concerns may have a deleterious impact on the willingness of clinicians and industry to participate in future clinical trials.
REPORTING AND DATA ACCESS Publication and reporting of final results of AIS trials are often suboptimal in spite of recommendations to adhere to guidelines in publications. 60 Publication of trial method design details should be mandated. Reporting standards improved after the addition of Consolidated Standards of Reporting Trials (CONSORT) guidelines. 10 Similar guidelines and standards for reporting AIS endovascular trials have been proposed. 60 Standardization of reporting and data access is increasingly demanded by regulators and journals and would improve trial credibility and the ability to compare trial results. CONCLUSION There are limited numbers of AIS interventional RCTs and single-arm prospective trials (selected ones are listed in tables 2 and 5). This scarcity underscores the significant challenges in designing trials in AIS. To address such complexity, it is critical to choose the most suitable outcome measures, control groups, and innovative overall designs.
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